CAMBRIDGE, Mass., June 15 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals
Incorporated (Nasdaq: VRTX) today announced that the underwriters have
exercised in full their over-allotment option to purchase 1,762,500 shares of
common stock at a public offering price of $13.00 per share. Upon the closing
of the purchase of the over-allotment shares, a total of 13,512,500 shares of
common stock will have been sold in the offering by Vertex, resulting in gross
proceeds, before commissions and expenses, of $175.7 million.
Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as the sole book-
running manager in this offering. J.P. Morgan Securities Inc. and UBS
Securities LLC acted as co-managers.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
any such state. A shelf registration statement relating to the shares of
common stock has previously been filed with, and declared effective by, the
Securities and Exchange Commission. This offering was made only by means of a
prospectus, including a prospectus supplement, forming a part of the effective
registration statement. A copy of the prospectus can be obtained from Merrill
Lynch's prospectus department, at 4 World Financial Center, New York, NY
10080, 212-449-1000.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company
committed to the discovery and development of breakthrough small molecule
drugs for serious diseases. The Company's strategy is to commercialize its
products both independently and in collaboration with major pharmaceutical
companies. Vertex's product pipeline is principally focused on viral
diseases, inflammation, autoimmune diseases and cancer. Vertex co-promotes
the HIV protease inhibitor, Lexiva(R), with GlaxoSmithKline.
Lexiva(R) is a registered trademark of the GlaxoSmithKline group of
companies.
Vertex's press releases are available at http://www.vrtx.com
Vertex Contacts:
Lynne H. Brum, VP, Corporate Communications and Financial Planning,
(617) 444-6614
Michael Partridge, Director, Corporate Communications, (617) 444-6108
Lora Pike, Manager, Investor Relations, (617) 444-6755
SOURCE Vertex Pharmaceuticals Incorporated
 back to top
Related links:
http://www.vrtx.com
Company News On-Call:
http://www.prnewswire.com/comp/938395.html
CONTACT:
Lynne H. Brum, VP, Corporate Communications
and Financial Planning, +1-617-444-6614, or Michael Partridge,
Director, Corporate Communications, +1-617-444-6108, or Lora
Pike, Manager, Investor Relations, +1-617-444-6755 all of Vertex
|
